Brain Protection in Schizophrenia, Mood and Cognitive Disorders
Samenvatting
Neuroprotection is a novel perspective for the treatment of disorders that lead to neurodegeneration and disabilities as a result of deterioration of neurons due to apoptosis, oxidative stress, excitotoxicity, and other mechanisms. These mechanisms have implications not only for neurodegenerative disorders, but also for schizophrenia, mood and cognitive disorders. The purpose of this book is to provide an up-to-date overview of basic and clinical studies concerning the neuroprotective approach, mechanisms, and several compounds with neuroprotective properties that may contribute to more efficacious treatment of major mental health disorders.
The book is divided into two sections. The first section serves as an introduction and overview of conceptual issues of the neuroprotective approach, and some neurobiological advances. Chapters in this section review definitions, perspectives, and issues that provide a conceptual base for the rest of the book. In addition, this part includes chapters in which the authors present and discuss the findings from basic studies of neurodegenerative mechanisms that are associated with the pathogenesis of major mental health disorders. The second section focuses on findings obtained from clinical trials with neuroprotective compounds, and neuromodulatory techniques. The take-home message is that principles of the neuroprotective approach may be applied to treatment of schizophrenia, mood and cognitive disorders. Contributors to this book are among the most active investigators and clinicians in the field who provide new perspectives not only clarifying ongoing controversies but also propose diverse aspects and new insights to neuroprotection.
This book is intended for a broad readership, which includes a broad spectrum of readers including neuroscientists, psychiatrists, neurologists, pharmacologists, clinical psychologists, general practitioners, geriatricians, graduate students, and policy makers in the fields of mental health.
Specificaties
Inhoudsopgave
Contributors
Content
Part I. Neuroprotective Strategies and Mechanisms
The brain protection of patients with neuropsychiatric disorders. Ehud Susser, and Michael S. Ritsner
Towards a new paradigm in neuroprotection and neuroplasticity. Dafin F. Muresanu
What protects patients with schizophrenia from developing Alzheimer pathology? Hans-Gert Bernstein, Theresia S. Ernst, Uwe Lendeckel, Henrik Dobrowolny, Johann Steiner, Bernhard Bogerts
Assessing neurodegeneration in vivo in schizophrenia using magnetic resonance. Jean Théberge
Vulnerability of the brain to neuropsychiatric disorders resulting from abnormal thyroid hormone or vitamin D homeostasis. Sarah J. Bailey and Peter J. McCaffery
Phosphatidylinositol 3-kinase/glycogen synthase kinase and mitogen-activated protein kinase signalling cascades in neuronal cell survival: What the neurotrophins have taught us, and implications for neuropsychiatric disorders. Stephen D. Skaper
One-compound-multi-targets at amyloid b cascade offered by bis(7)-Cognitin, a novel anti-Alzheimer’s dimmer. Wenming Li, Hongjun Fu, Moussa B.H. Youdim, Yuanping Pang, Yifan Han
Common pathways to neurodegeneration and co-morbid depression. Darcy Litteljohn, Emily N. Mangano, and Shawn Hayley
Breakdown of the blood-brain barrier in stress alters cognitive dysfunction and induces brain pathology. New perspective for neuroprotective strategies. Hari S Sharma
Oxidative stress and neurodegeneration: An inevitable consequence of aging? Implications for therapy. Roberto Rodrigues, David J. Bonda, George Perry, Rudy J. Castellani, Gemma Casadesus, Hyoung-gon Lee, Hyun-Pil Lee, Xinglong Wang, Xiongwei Zhu, Robert B. Petersen, Mark A. Smith
Carbon nanotubes as electricalinterfaces with neurons. William Lee and Vladimir Parpura
Part II. Neuroprotective Treatment and Neuromodulation
Is a neuroprotective therapy suitable for schizophrenia patients? Michael S. Ritsner
Recombinant human erythropoietin: Novel approach to neuroprotection and neuroregeneration in schizophrenia. Hannelore Ehrenreich, Martin Begemann, Claudia Bartels and Henning Krampe
Neuroprotective agents in mood disorders: pathophysiological and therapeutic implications. Giacomo Salvadore, Husseini K Manji
Neuroprotection in bipolar disorder. Chris Aiken
New antiepileptic drugs in neuropsychiatric disorders – basic and clinical pharmacology. Cecilie Johannessen Landmark and Svein I. Johannessen
The neuroprotective efficacy of vitamins. Chanoch Miodownik, Vladimir Lerner
Smoking and mental disorders: Focus on neuroprotection. Tsafrir Loebl
Inhibitor of glycine transporter-1 improves the functional outcome of schizophrenia. Christina Hui, and Guochuan Emil Tsai
The role of oxytocin in neuropsychiatric disorders: Concepts and Mechanisms. Raz Levin, Shany Edelman, Idan Shalev, Richard P. Ebstein and Uriel Heresco-Levy
Neuromodulation for neuropsychiatric disorders: Novel techniques - Vagus Nerve Stimulation, Transcranial Magnetic Stimulation, Transcranial Direct Current Stimulation, and Deep Brain Stimulation. Russell J Andrews
Index
